Krystal Biotech Future Growth

Future criteria checks 5/6

Krystal Biotech is forecast to grow earnings and revenue by 43.6% and 35% per annum respectively. EPS is expected to grow by 41% per annum. Return on equity is forecast to be 19.1% in 3 years.

Key information

43.6%

Earnings growth rate

41.0%

EPS growth rate

Biotechs earnings growth	24.0%
Revenue growth rate	35.0%
Future return on equity	19.1%
Analyst coverage	Good
Last updated	29 Apr 2024

Recent future growth updates

Recent updates

Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch

Feb 28

Krystal Biotech: Ready For Launch

Feb 20

We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth

Jan 02

Krystal Biotech cleared to file EU marketing application for rare skin disease therapy

Sep 22

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

Aug 30

Krystal Biotech: Solid Performance, Let's Keep Holding

Aug 18

Krystal Biotech GAAP EPS of -$1.10 misses by $0.07

Aug 08

Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis

Aug 01

Krystal Biotech: High Potential, Buy-At-Dips Stock

May 25

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Apr 20

Krystal Biotech: The Future Looks More And More Derisked

Feb 21

Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications

Nov 30

Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout

Sep 27

Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation

Sep 25

Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth

Jun 17

Krystal Biotech EPS misses by $0.16

May 10

Krystal Biotech provides update on pivotal GEM-3 study of B-VEC for DEB

Apr 26

Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation

Mar 02

Krystal Biotech secures $125 capital via equity raise

Feb 03

Krystal Biotech lays out catalysts for 2021

Jan 07

Earnings and Revenue Growth Forecasts

NasdaqGS:KRYS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	578	252	335	N/A	6
12/31/2025	404	135	230	150	8
12/31/2024	260	43	107	72	10
12/31/2023	51	11	-101	-89	N/A
9/30/2023	9	-30	-119	-104	N/A
6/30/2023	N/A	-140	-130	-102	N/A
3/31/2023	N/A	-135	-152	-111	N/A
12/31/2022	N/A	-140	-154	-101	N/A
9/30/2022	N/A	-130	-188	-99	N/A
6/30/2022	N/A	-115	-182	-87	N/A
3/31/2022	N/A	-104	-137	-54	N/A
12/31/2021	N/A	-70	-116	-48	N/A
9/30/2021	N/A	-58	-70	-35	N/A
6/30/2021	N/A	-52	-52	-35	N/A
3/31/2021	N/A	-43	-45	-30	N/A
12/31/2020	N/A	-32	-41	-26	N/A
9/30/2020	N/A	-27	-35	-25	N/A
6/30/2020	N/A	-22	-29	-23	N/A
3/31/2020	N/A	-20	-28	-22	N/A
12/31/2019	N/A	-19	-25	-19	N/A
9/30/2019	N/A	-17	-21	-15	N/A
6/30/2019	N/A	-16	-18	-13	N/A
3/31/2019	N/A	-13	-14	-10	N/A
12/31/2018	N/A	-11	-12	-9	N/A
9/30/2018	N/A	-9	-9	-8	N/A
6/30/2018	N/A	-11	-7	-7	N/A
3/31/2018	N/A	-10	-6	-6	N/A
12/31/2017	N/A	-8	-4	-4	N/A
9/30/2017	N/A	-7	N/A	-3	N/A
6/30/2017	N/A	-2	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KRYS's forecast earnings growth (43.6% per year) is above the savings rate (2.4%).

Earnings vs Market: KRYS's earnings (43.6% per year) are forecast to grow faster than the US market (14.1% per year).

High Growth Earnings: KRYS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: KRYS's revenue (35% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: KRYS's revenue (35% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: KRYS's Return on Equity is forecast to be low in 3 years time (19.1%).

Krystal Biotech Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus EPS estimates increase by 11%

Price target increased by 14% to US$176

Forecast breakeven date moved forward to 2024

Consensus revenue estimates decrease by 11%, EPS upgraded

Consensus revenue estimates decrease by 11%, EPS upgraded

Consensus revenue estimates increase by 28%

Recent updates

Krystal Biotech, Inc. to Report Q1, 2024 Results on May 06, 2024

Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Consensus EPS estimates increase by 11%

Krystal Biotech, Inc., Annual General Meeting, May 17, 2024

Founder notifies of intention to sell stock

Executive VP & Chief Accounting Officer notifies of intention to sell stock

Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch

Price target increased by 14% to US$176

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

Krystal Biotech, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Krystal Biotech: Ready For Launch

Executive VP & Chief Accounting Officer notifies of intention to sell stock

Krystal Biotech Receives Permanent J-Code (J3401) for VYJUVEK®

We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth

Founder notifies of intention to sell stock

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for Vyjuvek for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for Vyjuvek for the Treatment of Dystrophic Epidermolysis Bullosa

Consensus revenue estimates decrease by 11%, EPS upgraded

Krystal Biotech, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Consensus revenue estimates decrease by 11%, EPS upgraded

Krystal Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for KB408 for Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

Founder notifies of intention to sell stock

Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth

Consensus revenue estimates increase by 28%

Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?

Price target increased by 8.8% to US$148

Krystal Biotech, Inc. Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707

Krystal Biotech, Inc.(NasdaqGM:KRYS) dropped from Russell Small Cap Comp Value Index

Lead Independent Director recently sold US$6.4m worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$813k worth of stock

Founder recently sold US$2.9m worth of stock

Founder notifies of intention to sell stock

FDA Approves New Product Utilizing Berkshire Sterile Excipient Gel to Treat 'Butterfly Children'

Consensus revenue estimates increase by 28%

Krystal Biotech, Inc. announced that it expects to receive $159.999933 million in funding from Avoro Capital Advisors LLC, Redmile Group, LLC, Braidwell LP, Frazier Life Sciences Management, LP, Lighthouse Investment Partners, LLC

Executive VP & Chief Accounting Officer notifies of intention to sell stock

No longer forecast to breakeven

Krystal Biotech, Inc. Receives FDA Approval for the First-Ever Redosable Gene Therapy, Vyjuvek™? (Beremagenegeperpavec-Svdt) for the Treatment of Dystrophic Epidermolysis Bullosa

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

Price target increased by 7.2% to US$115

No longer forecast to breakeven

Founder notifies of intention to sell stock

Chairman of Scientific Advisory Board notifies of intention to sell stock

Chairman of Scientific Advisory Board notifies of intention to sell stock

Independent Director recently sold US$3.3m worth of stock

Forecast breakeven date moved forward to 2024

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Founder notifies of intention to sell stock

Krystal Biotech, Inc. Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa

Forecast to breakeven in 2025

Krystal Biotech, Inc. Announces New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech cleared to file EU marketing application for rare skin disease therapy

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

US Food and Drug Administration Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa

Krystal Biotech: Solid Performance, Let's Keep Holding

Consensus revenue estimates fall by 90%

Founder notifies of intention to sell stock

Krystal Biotech GAAP EPS of -$1.10 misses by $0.07

Krystal Biotech, Inc. Receives Fda Acceptance of Kb407 Ind Application for Cystic Fibrosis Clinical Trial

Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech: High Potential, Buy-At-Dips Stock

Consensus EPS estimates fall by 16%

No longer forecast to breakeven

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely